On December 15, the European Medicines Agency (EMA) issued a positive scientific opinion for the pediatric praziquantel arpraziquantel.
arpraziquantel is a drug being developed to treat schistosomiasis in children.
The Pediatric Praziquantel Consortium is leading the development of the drug, with Astellas Pharma Inc. participating from Japan.
The Global Health Innovative Technology Fund (GHIT Fund) is also funding the development.
The EMA's decision is expected to further advance efforts to bring arpraziquantel into the hands of children.
arpraziquantel is a drug being developed to treat schistosomiasis in children.
The Pediatric Praziquantel Consortium is leading the development of the drug, with Astellas Pharma Inc. participating from Japan.
The Global Health Innovative Technology Fund (GHIT Fund) is also funding the development.
The EMA's decision is expected to further advance efforts to bring arpraziquantel into the hands of children.
